Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Common Equity (2020 - 2025)

Historic Common Equity for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $401.2 million.

  • Apellis Pharmaceuticals' Common Equity rose 6918.28% to $401.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.2 million, marking a year-over-year increase of 6918.28%. This contributed to the annual value of $228.5 million for FY2024, which is 1748.81% up from last year.
  • Apellis Pharmaceuticals' Common Equity amounted to $401.2 million in Q3 2025, which was up 6918.28% from $156.3 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Common Equity's 5-year high stood at $462.2 million during Q1 2022, with a 5-year trough of -$334.4 million in Q2 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' median Common Equity value was $228.5 million (recorded in 2024), while the average stood at $187.3 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Common Equity tumbled by 16097.15% in 2021, and later skyrocketed by 79479.85% in 2022.
  • Apellis Pharmaceuticals' Common Equity (Quarter) stood at $198.7 million in 2021, then dropped by 14.49% to $169.9 million in 2022, then rose by 14.51% to $194.5 million in 2023, then increased by 17.49% to $228.5 million in 2024, then surged by 75.54% to $401.2 million in 2025.
  • Its Common Equity was $401.2 million in Q3 2025, compared to $156.3 million in Q2 2025 and $164.2 million in Q1 2025.